Transarterial Chemoembolization (TACE) Plus Sorafenib Compared to TACE Alone in Transplant Recipients with Hepatocellular Carcinoma: An Institution Experience

Transarterial Chemoembolization (TACE) Plus Sorafenib Compared to TACE Alone in Transplant Recipients with Hepatocellular Carcinoma: An Institution Experience

Background: Hepatocellular carcinoma (HCC) is the sixth most common malignancy and the third most common cause of cancer-related mortality worldwide. Transarterial chemoembolization has shown survival benefits in patients with early to intermediate-stage HCC, becoming the standard of care and recomm...

Full description

Bibliographic Details
Main Authors: Maen Abdelrahim, David Victor, Abdullah Esmail, Sudha Kodali, Edward A. Graviss, Duc T. Nguyen, Linda W. Moore, Ashish Saharia, Robert McMillan, Joy N. Fong, Ahmed Uosef, Mahmoud Elshawwaf, Kirk Heyne, Rafik M. Ghobrial
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Cancers
Subjects:
hepatocellular carcinoma
TACE
immunotherapy
LT
TKI
Milan criteria
Online Access:https://www.mdpi.com/2072-6694/14/3/650

Internet

https://www.mdpi.com/2072-6694/14/3/650

Similar Items